Compare · GILD vs KLRS
GILD vs KLRS
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Kalaris Therapeutics Inc. (KLRS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and KLRS operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $155.82B, about 1603.2x KLRS ($97.2M).
- Over the past year, GILD is up 14.0% and KLRS is up 29.6% - KLRS leads by 15.7 points.
- GILD has been more active in the news (20 items in the past 4 weeks vs 10 for KLRS).
- GILD has more recent analyst coverage (25 ratings vs 8 for KLRS).
- Company
- Gilead Sciences Inc.
- Kalaris Therapeutics Inc.
- Price
- $125.46-2.11%
- $4.09-3.54%
- Market cap
- $155.82B
- $97.2M
- 1M return
- -4.46%
- -19.09%
- 1Y return
- +13.97%
- +29.64%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2020
- News (4w)
- 20
- 10
- Recent ratings
- 25
- 8
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
- Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
- GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE
- Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
- Chairman & CEO O'Day Daniel Patrick sold $1,971,847 worth of shares (15,000 units at $131.46) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 617,567 units (SEC Form 4)
- Gilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
- Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)
- FDA Approval for HEPCLUDEX issued to GILEAD SCIENCES INC
- FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
- Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
Latest KLRS
- SEC Form 4 filed by Director Jovan-Embiricos Morana
- SEC Form 4 filed by Director Ferrara Napoleone
- SEC Form 4 filed by Director Hallal David
- SEC Form 4 filed by Director Akkaraju Srinivas
- SEC Form 4 filed by Director Dybbs Michael
- SEC Form 4 filed by Director Adamis Anthony P
- SEC Form 4 filed by Director Patterson Leone D
- SEC Form 8-K filed by Kalaris Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Kalaris Therapeutics Inc.
- Director Akkaraju Srinivas bought $1,179,969 worth of shares (244,300 units at $4.83), disposed of 66,906 shares and acquired 19,408 shares (SEC Form 4)